KIA
SUPN icon

KLR Investment Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

KLR Investment Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$231K Sell
7,785
-125
-2% -$3.72K 0.17% 166
2023
Q4 		$229K Buy
7,910
+249
+3% +$6.6K 0.17% 171
2023
Q3 		$278K Sell
7,661
-270
-3% -$8.22K 0.25% 135
2023
Q2 		$238K Sell
7,931
-30
-0.4% -$1.05K 0.2% 162
2023
Q1 		$288K Sell
7,961
-1,893
-19% -$72.8K 0.25% 131
2022
Q4 		$351K Buy
+9,854
New +$342K 0.29% 113

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

KLR Investment Advisors's SUPN Position: Q1 2024 in Review

KLR Investment Advisors reduced its Supernus Pharmaceuticals (SUPN) stake by 1.6% in Q1 2024, selling an estimated $3.72K and leaving 7,785 shares worth $231K. The position accounts for 0.17% of the portfolio, ranked #166.

KLR Investment Advisors first reported a position in SUPN in Q4 2022 and has held it in 6 quarters since. The position peaked at $351K in Q4 2022. 250 funds tracked by Wall St. Rank hold SUPN as of Q1 2024.

  • KLR Investment Advisors held 7,785 shares of Supernus Pharmaceuticals worth $231K as of Q1 2024.
  • KLR Investment Advisors sold 125 Supernus Pharmaceuticals shares in Q1 2024, an estimated $3.72K.
  • Supernus Pharmaceuticals made up 0.17% of KLR Investment Advisors's portfolio in Q1 2024, its #166 holding.
  • KLR Investment Advisors first reported a position in Supernus Pharmaceuticals in Q4 2022 and has held it in 6 quarters since.
  • KLR Investment Advisors's Supernus Pharmaceuticals position peaked at $351K in Q4 2022.
  • 250 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2024.

Based on KLR Investment Advisors's 13F filing for Q1 2024, filed 23 Apr 2024.